However, despite the clinical efficacy of current CFTR modulators in restoring the activity of defective CFTR [26], some patients cannot be treated or show persistent pulmonary infections (mainly due to P. aeruginosa) that remain a major challenge, mostly in advanced stages of lung disease [27]. The gene discussed is CFTR; the disease is lung disorder.